These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35904479)

  • 21. Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma.
    Gamboa-Cedeño AM; Díaz M; Cristaldo N; Otero V; Schutz N; Fantl D; Cugliari S; Zerga M; Rojas-Bilbao E; Jauk F; García Rivello H; Nuñez M; Ranuncolo SM
    Life Sci; 2021 Mar; 268():118979. PubMed ID: 33421528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.
    Vogiatzi F; Heymann J; Müller K; Winterberg D; Drakul A; Rösner T; Lenk L; Heib M; Gehlert CL; Cario G; Schrappe M; Claviez A; Bornhauser B; Bourquin JP; Bomken S; Adam D; Frielitz FS; Maecker-Kolhoff B; Stanulla M; Valerius T; Peipp M; Kellner C; Schewe DM
    Blood Adv; 2022 Aug; 6(16):4847-4858. PubMed ID: 35820018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model.
    Manriquez Roman C; Sakemura RL; Kimball BL; Jin F; Khadka RH; Adada MM; Siegler EL; Johnson AJ; Kenderian SS
    J Vis Exp; 2023 Feb; (192):. PubMed ID: 36847405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of failure of chimeric antigen receptor T-cell therapy.
    Li X; Chen W
    Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma.
    Flanagan L; Coughlan A; Cosgrove N; Roe A; Wang Y; Gilmore S; Drozdz I; Comerford C; Ryan J; Minihane E; Parvin S; O'Dwyer M; Quinn J; Murphy P; Furney S; Glavey S; Chonghaile TN; Foundation LR; Ireland SF; Research BC
    Haematologica; 2024 Sep; 109(9):2930-2943. PubMed ID: 38511268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
    Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
    Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.
    Deng Y; Diepstraten ST; Potts MA; Giner G; Trezise S; Ng AP; Healey G; Kane SR; Cooray A; Behrens K; Heidersbach A; Kueh AJ; Pal M; Wilcox S; Tai L; Alexander WS; Visvader JE; Nutt SL; Strasser A; Haley B; Zhao Q; Kelly GL; Herold MJ
    Nat Commun; 2022 Aug; 13(1):4739. PubMed ID: 35961968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
    Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
    Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
    [No Abstract]   [Full Text] [Related]  

  • 32. Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.
    Bodo J; Zhao X; Durkin L; Souers AJ; Phillips DC; Smith MR; Hsi ED
    Oncotarget; 2016 Oct; 7(43):70000-70010. PubMed ID: 27661108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
    Deng S; Derebail S; Weiler VJ; Fong Ng J; Maroto-Martin E; Chatterjee M; Giorgetti G; Chakraborty C; Kalhotra P; Du T; Yao Y; Prabhala R; Shammas M; Gulla A; Aktas Samur A; Samur MK; Qiu L; Anderson KC; Fulciniti M; Munshi NC
    Blood Adv; 2024 Aug; 8(15):4025-4034. PubMed ID: 38861273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade.
    Kohlhapp FJ; Haribhai D; Mathew R; Duggan R; Ellis PA; Wang R; Lasater EA; Shi Y; Dave N; Riehm JJ; Robinson VA; Do AD; Li Y; Orr CJ; Sampath D; Raval A; Merchant M; Bhathena A; Salem AH; Hamel KM; Leverson JD; Donawho C; Pappano WN; Uziel T
    Cancer Discov; 2021 Jan; 11(1):68-79. PubMed ID: 32887697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.
    Seyfried F; Demir S; Hörl RL; Stirnweiß FU; Ryan J; Scheffold A; Villalobos-Ortiz M; Boldrin E; Zinngrebe J; Enzenmüller S; Jenni S; Tsai YC; Bornhauser B; Fürstberger A; Kraus JM; Kestler HA; Bourquin JP; Stilgenbauer S; Letai A; Debatin KM; Meyer LH
    Cell Death Dis; 2019 Jul; 10(8):571. PubMed ID: 31358732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma.
    Li M; Yu H; Qi F; Ye Y; Hu D; Cao J; Wang D; Mi L; Wang Z; Ding N; Ping L; Shu S; Zhu J
    Hematol Oncol; 2022 Oct; 40(4):596-608. PubMed ID: 35477179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
    Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
    Guièze R; Liu VM; Rosebrock D; Jourdain AA; Hernández-Sánchez M; Martinez Zurita A; Sun J; Ten Hacken E; Baranowski K; Thompson PA; Heo JM; Cartun Z; Aygün O; Iorgulescu JB; Zhang W; Notarangelo G; Livitz D; Li S; Davids MS; Biran A; Fernandes SM; Brown JR; Lako A; Ciantra ZB; Lawlor MA; Keskin DB; Udeshi ND; Wierda WG; Livak KJ; Letai AG; Neuberg D; Harper JW; Carr SA; Piccioni F; Ott CJ; Leshchiner I; Johannessen CM; Doench J; Mootha VK; Getz G; Wu CJ
    Cancer Cell; 2019 Oct; 36(4):369-384.e13. PubMed ID: 31543463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.